Nouscom appoints Neil Gallagher as independent advisor

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announces today that Neil Gallagher, MD, PhD, has been appointed as an Independent Advisor to Nouscom’s Board of Directors and will also Chair the Company’s R&D Committee.

Dr. Gallagher’s leadership will be essential in guiding Nouscom’s clinical development strategy and activities as it advances its wholly owned clinical pipeline through multiple clinical proof of concept readouts.

Dr. Gallagher has over 20 years of experience within large, global pharmaceutical R&D organizations and emerging biopharmaceutical companies. Throughout his career, he has led end-to-end drug development programs that have resulted in the approval of multiple innovative medicines, ranging from small molecules to biologics across several therapeutic areas, including oncology and immunology.

Since April 2023, he has served as President of R&D at Syndax Pharmaceuticals, a clinical-stage oncology company developing targeted first-in-class cancer therapies. Prior to this, he led multiple development programs through approval globally and oversaw asset strategy and portfolio management across several therapeutic areas as Chief Medical Officer and Head of Development at AbbVie. Other roles include Head of Global Oncology Development at AbbVie, Head of Development for Oncology and Inflammation at Amgen, and Global Program Head at Novartis Oncology. He has also held clinical development roles at AstraZeneca and Astex Therapeutics.

Before entering the industry, Dr. Gallagher received his medical degree from Trinity College, Dublin, and completed his Fellowship in Gynaecological Oncology at the Institute for Cancer Studies, University of Birmingham, UK.

Dr. Marina Udier, Chief Executive Officer of Nouscom, commented, “We are thrilled to welcome Neil as Independent Advisor to our Board and Chair of our R&D Committee. His extensive experience and leadership in clinical drug development and registration will provide invaluable insights that will allow us to further accelerate progress across our clinical portfolio of neoantigen-based cancer vaccines, including an ongoing randomized Phase 2 trial of NOUS-209 in MSI colorectal cancer.”

Dr. Goran Ando, Independent Chair of Nouscom’s Board, said, “Together with the experience of our existing Board Members, I look forward to Neil’s contributions as Nouscom reports multiple clinical trial readouts and navigates the next exciting steps in its growth.”

Dr. Neil Gallagher added, “I am truly excited to be working with Nouscom’s Board and management and look forward to sharing my knowledge and expertise to guide and support the development of its clinical pipeline. Nouscom’s dedication to generating safe, innovative, and potent next-generation cancer immunotherapies that selectively eliminate tumor cells and pre-cancerous lesions could be potentially life-changing for patients and I look forward to helping the Company achieve this.”